USAU vs. OPNT, AMLI, ASM, NB, WWR, BVN, LZM, NEXA, BHP, and SCCO
Should you be buying U.S. Gold stock or one of its competitors? The main competitors of U.S. Gold include Opiant Pharmaceuticals (OPNT), American Lithium (AMLI), Avino Silver & Gold Mines (ASM), NioCorp Developments (NB), Westwater Resources (WWR), Compañía de Minas Buenaventura S.A.A. (BVN), Lifezone Metals (LZM), Nexa Resources (NEXA), BHP Group (BHP), and Southern Copper (SCCO).
U.S. Gold (NASDAQ:USAU) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both small-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.
U.S. Gold has a net margin of 0.00% compared to Opiant Pharmaceuticals' net margin of -147.90%. U.S. Gold's return on equity of -40.73% beat Opiant Pharmaceuticals' return on equity.
6.6% of U.S. Gold shares are held by institutional investors. Comparatively, 42.4% of Opiant Pharmaceuticals shares are held by institutional investors. 9.8% of U.S. Gold shares are held by insiders. Comparatively, 25.2% of Opiant Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
U.S. Gold has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Opiant Pharmaceuticals has higher revenue and earnings than U.S. Gold. U.S. Gold is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, U.S. Gold had 7 more articles in the media than Opiant Pharmaceuticals. MarketBeat recorded 7 mentions for U.S. Gold and 0 mentions for Opiant Pharmaceuticals. U.S. Gold's average media sentiment score of 0.91 beat Opiant Pharmaceuticals' score of 0.00 indicating that U.S. Gold is being referred to more favorably in the media.
Opiant Pharmaceuticals received 65 more outperform votes than U.S. Gold when rated by MarketBeat users. However, 69.82% of users gave U.S. Gold an outperform vote while only 64.23% of users gave Opiant Pharmaceuticals an outperform vote.
U.S. Gold currently has a consensus target price of $14.50, suggesting a potential upside of 148.71%.
Summary
U.S. Gold beats Opiant Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get U.S. Gold News Delivered to You Automatically
Sign up to receive the latest news and ratings for USAU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding USAU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
U.S. Gold Competitors List
Related Companies and Tools
